6917.TWO Andros Pharmaceuticals Co.,Ltd
- Market cap
- TWD 1.83B
- P/E
- -
- P/B
- 3.80x
- ROE
- -10.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6917.TWO undervalued?
Graham numberThe Graham number of Andros Pharmaceuticals Co.,Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Andros Pharmaceuticals Co.,Ltd fundamental analysis
No fundamental analysis for Andros Pharmaceuticals Co.,Ltd yet.
Andros Pharmaceuticals Co.,Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Andros Pharmaceuticals Co.,Ltd
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. …
Full company profileAndros Pharmaceuticals Co.,Ltd financial statements
Andros Pharmaceuticals Co.,Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 3.27M | 13.3M | 1.71M | 805K | 203K | 5.55M |
| Gross Profit | - | 2.38M | 8.59M | 966K | 313K | 10.0K | 1.80M |
| Operating Income | -60.5M | -42.4M | -36.6M | -40.7M | -73.7M | -89.6M | -75.6M |
| EBITDA | -60.5M | -27.8M | -29.7M | -34.3M | -61.5M | -71.6M | -46.5M |
| Net Income | - | -35.9M | -37.1M | -41.2M | -68.2M | -78.3M | -53.8M |
| EPS | - | -1.33 | -1.37 | -1.25 | -1.87 | -1.70 | -0.97 |
| Balance Sheet | |||||||
| Total Assets | 187M | 153M | 120M | 330M | 529M | 441M | 559M |
| Total Liabilities | 59.9M | 63.0M | 51.6M | 50.1M | 58.0M | 47.3M | 43.3M |
| Shareholders' Equity | 127M | 90.4M | 68.7M | 279M | 471M | 394M | 516M |
| Cash & Short-term Investments | 127M | 92.7M | 67.7M | 255M | 443M | 353M | 53.8M |
| Total Debt | 43.4M | 38.8M | 34.6M | 31.3M | 27.1M | 22.0M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -53.0M | -26.7M | -35.9M | -35.8M | -46.6M | -78.9M | -45.4M |
| Capital Expenditure | 1.16M | 2.09M | 0.00 | 46.0K | 582K | 4.52M | 990K |
| Free Cash Flow | -54.1M | -28.8M | -35.9M | -35.8M | -47.2M | -83.4M | -46.4M |
| Ratios | |||||||
| ROE | - | -39.7% | -54.1% | -14.7% | -14.5% | -19.9% | -10.4% |
| ROA | - | -23.4% | -30.9% | -12.5% | -12.9% | -17.7% | -9.6% |
| Net Profit Margin | - | -1,098.1% | -278.9% | -2,403.7% | -8,467.0% | -38,561.1% | -969.3% |
| Debt to Equity | 0.34x | 0.43x | 0.50x | 0.11x | 0.06x | 0.06x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Andros Pharmaceuticals Co.,Ltd dividends
Andros Pharmaceuticals Co.,Ltd has not paid dividends in the last 7 fiscal years.
Who owns Andros Pharmaceuticals Co.,Ltd
Ownership data of Andros Pharmaceuticals Co.,Ltd is not available yet.
Andros Pharmaceuticals Co.,Ltd company profile
- Company name
- Andros Pharmaceuticals Co.,Ltd
- Ticker
- 6917.TWO
- ISIN
- TW0006917008
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 22, Shengyi Road, Zhubei, Taiwan, 30261
- Phone
- 886 3 658 1866
- Website
- andros.com.tw
About Andros Pharmaceuticals Co.,Ltd
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.
Andros Pharmaceuticals Co.,Ltd management
1- Ming-Wen LeeManagerial Officer & Director